This Series paper supports SDG 3 by evaluating existing and emerging vaccines and vaccination campaigns against hepatitis B virus and other sexually transmitted infections, as well as other interventions such as PrEP for HIV

This article supports SDG 3 by highlighting the importance of hepatitis C elimination to prevent liver cancer in Latin America.

This article contributes to SDG 3 by developing predictive tools to improve clinical management of autoimmune hepatitis.

This Article supports SDG 3 by showing that international transmission of hepatitis C virus has occurred in recent years among men who have sex with men. This suggests that international coordination will be needed for microelimination in this population.

This Review supports SDG 3 by assessing the availablility of data for reporting elimination targets of mother-to-child transmission of HIV, hepatitis B, and syphilis, and reports on progress towards these targets in Pacific Island countries and territories.

This review supports SDG 3 as despite available antiviral therapy, hepatitis C virus (HCV) remains a global health burden and a prophylactic vaccine would help to eliminate the risk to develop chronic liver diseases. This paper uses data to draw a simplified model of virus entry, which highlights gaps in our current knowledge that warrant further research to fully understand this process at the atomic level.

This Article supports SDG 3 by evaluating shared-care models with hepatitis B virus testing in China, including an analysis of the cost-effectiveness and the impact on quality of life and mortality.

This Article supports SDG 3 by evaluating alanine transaminase antiviral treatments for hepatitis B virus infection in China. The authors suggest the optimal treatment coverage for both cost-effectiveness and mortality reduction based on their findings

This Article supports SDG 3 as the results show that two doses of the HEV 239 vaccine produces broad and likely functional immune responses against HEV that remain for at least two years. The safety profile was acceptable and a phase four study of HEV 239 in rural Bangladesh is feasible.

This article supports SDG 3 as chronic hepatitis B (HBV) and C virus (HCV) infections represent significant public health issues internationally. This paper aims to evaluate the efficacy of hepatitis B vaccination in HCV-related chronic liver disease and identify possible factors that may contribute to hypo-responsiveness in those patients.